Hapoalim is upgrading shares of Eli Lilly & Co. LLY from Hold to Buy. “We are also increasing our Price Target to $39,” Hapoalim writes.
“As a result of better-than-expected 1Q sales, we are increasing our 2011-2014 revenue estimates. Additionally as a result of higher than expected operating costs in 1Q we are increasing our 2011-2014 operating cost estimates. The net of these changes increases our 2011-2014 EPS estimates from $4.20, $3.62, $3.90 and $2.42, to $4.36, $3.83, $4.11 and $2.58, respectively. We are also rolling out a 2015 EPS estimate of $2.45.”
Eli Lilly currently trades at $35.62.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in